Research progress on drug therapy of hyperuricemia

doi:10.12092/j.issn.1009-2501.2019.05.017

Abstract

Abstract:

Hyperuricemia (HUA) is a metabolic disease resulting from either the overproduction of uric acid or reduced uric acid excretion. Chronic hyperuricemia and gout are associated with comorbidities such as hypertension, cardiovascular disease and chronic kidney disease (CKD). Timely and effective urate lowering therapy (ULT) is the key to reducing urate deposition, preventing gout attacks, reducing kidney damage, and reducing the incidence of other accompanying diseases. According to the different targets of drugs, uric acid lowering drugs can be divided into four categories: drugs that inhibit the production of uric acid, drugs that promote the excretion of uric acid, drugs that promote the dissolution of uric acid, and newly discovered drugs that can simultaneously inhibit the production of uric acid and promote the excretion of uric acid. Recently the development of the promising drugs, the introduction of drugs and the combination therapy have become the research focus.This paper reviews the research progress of uric acid-lowering drugs in recent years.

Key words: hyperuricemia, drug therapy, research progress

CLC Number:

R969.3

SUN Shanshan, QU Lianyue, DU Rongrong, LIN Jianyang. Research progress on drug therapy of hyperuricemia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 589-594.

References

［1］Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options［J］. BMC Medicine, 2017, 15(1):123.
［2］Juraschek SP, Gelber AC. Body mass index, obesity, and prevalent gout in the United States in 1988-1994 and 2007-2010［J］. Arthritis Care Res (Hoboken), 2013, 65(1):127-132.
［3］Chen C, Lü JM, Yao Q. Hyperuricemia-related diseases and xanthine oxidoreductase (XOR) inhibitors: an overview［J］. Med Sci Monit, 2016, 22:2501-2512.
［4］Day RO, Graham GG, Hicks M, et al. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol［J］. Clin Pharmacokinet, 2007, 46(8):623-644.
［5］Kao MP , Ang DS , Gandy SJ , et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease［J］. J Am Soc Nephrol, 2011, 22(7):1382-1389.
［6］Dubreuil M, Zhu Y, Zhang Y, et al. Allopurinol initiation and all-cause mortality in the general population［J］. Ann Rheum Dis, 2015, 74(7):1368-1372.
［7］Grimaldi-Bensouda L, Alpérovitch, A, Aubrun E, et al. Impact of allopurinol on risk of myocardial infarction［J］. Ann Rheum Dis, 2015, 74(5):836-842.
［8］White WB, Chohan S, Dabholkar A, et al. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities［J］. Am Heart J, 2012, 164(1):14-20.
［9］Schumacher HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial［J］. Arthritis Rheum, 2008, 59(11):1540-1548.
［10］Xu S, Liu X, Ming J, et al. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia ［J］. Int J Rheum Dis, 2015, 18(6):669-678.
［11］Li S, Yang H, Guo Y, et al. Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis［J］. Scientific reports, 2016, 6:33082.
［12］杨丹. 别嘌醇降尿酸治疗效益及药物经济学评价［D］. 北京协和医学院, 2016.
［13］Hosoya T, Ohno I, Nomura S, et al. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout［J］. Clin Exp Nephrol, 2014, 18(6):876-884.
［14］Hosoya T, Ogawa Y, Hashimoto H, et al. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study［J］. J Clin Pharm Ther, 2016, 41(3):290-297.
［15］Hosoya T, Ishikawa T, Ogawa Y, et al. Multicenter, open-label study of long-term topiroxostat (FYX-051) administration in japanese hyperuricemic patients with or without gout［J］. Clin Drug Investig, 2018, 38(12):1135-1143.
［16］Wada T, Hosoya T, Honda D, et al. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study)［J］. Clin Exp Nephrol, 2018,22(4):860-870.
［17］Bantia S, Harman L, Hollister A, et al. FRI0401 BCX4208, a novel enzyme inhibitor for chronic management of GOUT, shows a low risk of potential drug-drug interactions［J］. Ann Rheum Dis, 2013, 71(Suppl 3):450.
［18］Hollister AS, Dobo S, Maetzel A, et al. FRI0380 long-term safety of BCX4208 added to allopurinol in the chronic management of GOUT: Results of a phase 2 24-week blinded safety extension and vaccine challenge study［J］. Ann Rheum Dis, 2013, 71(Suppl 3):442-443.
［19］Finch A, Kubler P. The management of gout［J］. Australian Prescriber, 2016, 39(4):119-122.
［20］Chou HW, Chiu HT, Tsai CW, et al. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study［J］. Nephrol Dial Transplant, 2018, 33(9):1620-1627.
［21］曾小峰,陈耀龙. 2016中国痛风诊疗指南［J］. 浙江医学, 2017, 39(21):1823-1832.
［22］Miner JN, Tan PK, Hyndman D, et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney［J］. Arthritis Res Ther, 2016,18(1):214.
［23］Gillen M, Valdez S, Zhou D, et al. Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers［J］. Drug Des Devel Ther, 2016, 10:3555-3562.
［24］Tausche AK, Alten R, Dalbeth N, et al. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study［J］. Rheumatol, 2017, 56(12):2170-2178.
［25］陈光亮, 周媛凤, 张颖. 治疗痛风和高尿酸血症药物研究进展［J］. 中国临床药理学与治疗学, 2017, 22(1):104-109.
［26］Fitz-Patrick D, Roberson K, Niwa K, et al. Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two Phase II trials［J］. Mod Rheumatol, 2018:1-27.
［27］Yu YK, Yu F, Ye C, et al. Combination therapies of diacerein and febuxostat inhibit IL-1β responses and improve clinical symptoms in patients with refractory gout［J］. Am J Ther, 2017,24(3):e290-e297.
［28］韩建勤, 李继东, 罗萍,等. 氯沙坦和缬沙坦治疗高血压合并高尿酸血症的临床效果对比［J］. 重庆医学, 2016, 45(26):3707-3708.
［29］Poiley J, Steinberg AS, Choi YJ, et al. A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout ［J］. Arthritis Rheumatol, 2016, 68(8):2027-2034.
［30］Ahn SO, Ohtomo S, Kiyokawa J, et al. Stronger uricosuric effects of the novel selective URAT1 inhibitor UR-1102 lowered plasma urate in tufted capuchin monkeys to a greater extent than benzbromarone［J］. J Pharmacol Exp Ther, 2016, 357(1):157-166.
［31］Taniguchi T, Ashizawa N, Matsumoto K, et al. Uricosuric agents decrease the plasma urate level in rats by concomitant treatment with topiroxostat, a novel xanthine oxidoreductase inhibitor［J］. J Pharm Pharmacol, 2016, 68(1):76-83.
［32］Mandal AK, Mercado A, Foster A, et al. Uricosuric targets of tranilast［J］. Pharmacol Res Perspect, 2017, 5(2):e00291.
［33］McWherter C, Choi Y, Serrano R L, et al. Arhalofenate acid inhibits monosodium urate crystal-induced inflammatory responses through activation of AMP-activated protein kinase (AMPK) signaling［J］. Arthritis Res Ther, 2018, 20(1):204.
［34］Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study［J］. J Clin Oncol, 2010, 28(27):4207-4213.
［35］Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials［J］. JAMA, 2011,306(7):711-720.
［36］Yood RA, Ottery FD, Irish W, et al. Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials ［J］. BMC Res Notes, 2014, 7(1):54.
［37］Phase II Exploratory Clinical Study of KUX-1151 U.S. Department of Health and Human Services: Clinicaltrials.gov;2015.
［38］Warrell RP, Klukovits A, Barnes K, et al. Profound hypouricemia induced in human subjects by novel bifunctional inhibitors of xanthine oxidase and URAT1 ［abstract］. Arthritis Rheum,2014,66 (Suppl 10):S1-S1402.
［39］Saag KG, Fitz-Patrick D, Kopicko J, et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study)［J］. Arthritis Rheumatol, 2017, 69(1):203-212.
［40］Bardin T, Keenan RT, Khanna PP, et al. Lesinurad in combination with allopurinol: A randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)［J］. Ann Rheum Dis, 2017,76(5):811-820.
［41］Dalbeth N, Jones G, Terkeltaub R, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial［J］. Arthritis Rheumatol, 2017, 69(9):1903-1913.
［42］Fleischmann R, Winkle P, Miner JN, et al. Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study［J］. RMD Open, 2018, 4(1):e584.
［43］Shiramoto M, Liu S, Shen Z, et al. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: A phase 2a, open-label study［J］. Rheumatology (United Kingdom), 2018,57(9):1602-1610.
［44］Perez-Ruiz F, Dalbeth N. Combination urate-lowering therapy in the treatment of gout: What is the evidence［J］? Semin Arthritis Rheum, 2019,48(4):658-668.

[1]	LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui. Advances in targeted therapy for HER2-positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
[2]	ZHANG Li, LIN Xingyao, SHANG Yun, WANG Qiang. Progress on the pathological mechanism and treatment of frostbite [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 347-354.
[3]	LI Chenhao, YU Xihua, YAN Wenhao, CHAI Yuxia, LI Yanyan, LI Kun, LI Zeyun. Research progress on the relationship between pediatric epilepsy and vitamin D [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1299-1306.
[4]	LIU Dan, LIU Ming, JIN Liangyou, PAN Juan, XIN Haoru, LIU Mengyuan, LI Xin, ZHENG Kun, FENG Xiaoling. Research progress on the antitumor activity of costunolide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1168-1176.
[5]	LI Miao, YU Qinwei, JIANG Zhenzhou, ZHANG Luyong, . Regulatory mechanism of LDLR and research progress of its related diseases and drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 946-954.
[6]	LI Yuanfang, CUI Zhaoqiang. Treatment of hypertension complicated with hyperuricemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 428-432.
[7]	LU Xiaohong, HE Caifeng, Ci Chao, YUAN Tao. Progress in the treatment of mucosal pemphigoid [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1197-1200.
[8]	CHEN Wenjie, WANG Yabing, CHEN Xiaolin, REN Junling, ZHAO Wanjun, CHEN bin. Advances in the study of iodine-resistant differentiated thyroid cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 116-120.
[9]	HAO Haiping. Metabolic regulation and drug target discovery researches in China: Progress and prospect [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 955-963.
[10]	ZHAO Zhengqing, LI Yanpeng, XIANG Xiaoxia, ZHUANG Jianhua, ZHAO Zhongxin. Pathophysiology and cognitive behavioral therapy of chronic insomnia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 482-486.
[11]	CHEN Ying, YUAN Yonggui. Research progress in the treatment of depression with monome of Chinese herb, drug pairs, compound prescriptions and Chinese patent drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 586-593.
[12]	WU Dan, DIAO Yong, XU Xianxiang. Progress in research on hyperuricemia cell model [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 236-240.
[13]	PEI Qinghua, SUN Jianli. Research progress of Osimertinib acquired resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 105-112.
[14]	LIU Qingwu, CHEN Jia, MENG Yujiao, FENG Fang, GUO Xiwei, GUO Jianning, ZHANG Jinchao, LIN Yan, HE Xiujuan, LI Ping. Research progresses of wound repair by exosomes derived from mesenchymal stem cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 826-832.
[15]	CHEN Guangliang, ZHOU Yuanfeng, ZHANG Ying. Research progress in medicine for treating gout and hyperuricemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 104-109.